Annual General Meeting in Modus Therapeutics Holding AB (publ)
Today, the annual general meeting of 2022 was held in Modus Therapeutics Holding AB (publ). Below is a summary of the resolutions passed at the annual general meeting (all in accordance with the proposals presented in the notice to attend the meeting kept available at the company’s website www.modustx.com).
Modus Annual General Meeting on 11 May 2022 resolved in accordance with the following:
- That no dividend would be paid.
- To discharge the board members and the managing director from liability with respect to their management of the company for the financial year 2021.
- That the board of directors shall comprise three board members without any deputies.
- To re-elect the board members Viktor Drovta, Ellen Donnelly and Torsten Goesch and to re-elect Viktor Drovta as the chairman of the board.
- To re-elect Ernst & Young Aktiebolag as auditor.
- To adopt principles for the Nomination Committee, in accordance with the Nomination Committee’s proposal.
- To adopt new articles of association whereby the limits of the share capital and number of shares are amended.
- To authorize the board, for a period that does not extend past the date of the next annual general meeting, on one or several occasions, with or without pre-emptive rights for the shareholders, to resolve on the issue of new shares, convertibles and/or warrants.
For more information on Modus Therapeutics, please contact:
John Öhd, VD, Modus Therapeutics
Phone: +46 (0) 70 766 80 97
Email: john.ohd@modustx.com
Certified Adviser
Svensk Kapitalmarknadsgranskning AB
Phone: +46 11 32 30 732
Email: ca@skmg.se
***
About Modus Therapeutics and sevuparin
Modus Therapeutics is a Swedish biotechnology company headquartered in Stockholm that develops sevuparin with a focus on diseases with a high unmet medical need. The company's focus in the near future is to develop sevuparin for patients with sepsis / septic shock, which is a serious and often fatal condition. Modus Therapeutics is listed on the Nasdaq First North Growth market (“MODTX”). More information is available at www.modustx.com
Sevuparin is a clinical stage, innovative proprietary polysaccharide drug with a multimodal mechanism of action, including anti-inflammatory, anti-adhesive and anti-aggregate effects. Sevuparin is a heparinoid with markedly attenuated anti-coagulation features that allows severalfold higher doses to be given, compared to regular heparinoids, without the associated risk for bleeding side-effects. Two routes of administration of sevuparin are currently being tested – an IV formulation for in-patient administration and a subcutaneous formulation that allows ambulatory and home care administration